Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033992 · ClinicalTrials.gov registry record · NA
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
A NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma, sponsored by Children's Oncology Group.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT03033992 is a NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 80 participants, below the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target (11% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT03033992, a NA study of Malignant Glioma and Diffuse Intrinsic Pontine Glioma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Conditions Studied
Interventions
- DEVICE Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)
- COMBINATION_PRODUCT Concurrent Optune and RT followed by Optune System alone
Study Locations (11)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children's Hospital at Stanford University Medical Center - Palo Alto
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital of Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2031-07-21 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033992
The ClinicalTrials.gov registry entry for NCT03033992 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 40 other Malignant Glioma trials with a reported enrollment target (11% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) is the first listed.
NCT03033992 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT03033992 about?
NCT03033992 is a clinical study titled "Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG". This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation ther...
What is the current status of trial NCT03033992?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2017-04-04. Estimated completion is 2031-07-21.
What conditions does trial NCT03033992 study?
This clinical trial studies the following conditions: Malignant Glioma, Diffuse Intrinsic Pontine Glioma, Ependymoma.
What interventions are being tested in trial NCT03033992?
The interventions under investigation include: Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields) (DEVICE), Concurrent Optune and RT followed by Optune System alone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03033992?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033992 being conducted?
This trial has 11 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
-
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
COMPLETED · NA
-
Mapping of Electrical Properties in the Brain
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.